Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElixirr International Regulatory News (ELIX)

Share Price Information for Elixirr International (ELIX)

Share Price is delayed by 15 minutes
Get Live Data
700.00    0.00 (0.00%)
Bid:
694.00
Ask:
700.00
Spread: 6.00 (0.865%)
Market Cap: £346.93m
ELIX Live PriceLast checked at - London Stock Exchange

Intraday Elixirr International Share Chart

Trading Update

1 Feb 2022 07:00

RNS Number : 1912A
Elixirr International PLC
01 February 2022
 

ELIXIRR INTERNATIONAL PLC

("Elixirr", the "Company" or the "Group")

Trading Update

 

Elixirr International plc (AIM:ELIX), an established, global award-winning challenger consultancy, is pleased to provide an update on trading for the year ended 31 December 2021.

 

Trading through to the end of 2021 continued to be strong. The Group has continued to support its clients to address their key challenges, with Elixirr's services in relation to digital transformation and innovation in high demand.

 

Subject to the completion of the audit for the year ended 31 December 2021, the Group expects to record revenue of approximately £50.5m, above the market expectation of £47-50m. Adjusted EBITDA is expected to be approximately £15.5m, above the market expectation of £15.0m and within the range of 30-32% of revenue previously announced.

 

As at 31 December 2021, the Group had no debt with cash balances in excess of £31m.

 

The Group has continued to make good progress on all four of its strategic growth pillars, including:

· Stretching our current partner team - we achieved organic revenue growth in excess of 30% during 2021, including growth of approximately 100% in our US business

· Promoting partners from within the firm - we have promoted two experienced principals to partner on 1 January 2022

· Hiring new partners - six experienced partners joined the business over the course of 2021, with a number of them focused on accelerating the growth of our US business

· Buying complementary businesses - we completed the acquisition of The Retearn Group Limited in April 2021 and are seeing good traction with selling their procurement and self-funded transformation services into our client base. We remain focused on inorganic growth and are continuing to explore a number of other attractive acquisition opportunities with companies specialising in solving Board room issues, including in the US market which is the fastest growing part of our business.

The Directors expect further organic revenue and Adjusted EBITDA growth in 2022. A more detailed update on expectations for 2022 will be provided by the Directors in conjunction with the release of the full year results for the year ended 31 December 2021 on 4 April 2022.

 

For further Information please contact:

 

Elixirr International plc

Stephen Newton, CEO

Graham Busby, CFO

 

 

 

 

Public and Investor Relations contacts:

Caroline Pitt

 

finnCap Ltd (Nominated Adviser & Sole Broker)

Christopher Raggett, Kate Bannatyne (Corporate Finance)

Alice Lane, Sunila De Silva (ECM)

 

 

 

investor-relations@elixirr.com

 

 

+44 (0)20 7220 0500

 

 

About Elixirr International plc

Elixirr is an established global award-winning management consultancy, challenging the larger consultancies by delivering innovative and bespoke solutions to a repeat, globally-recognised client base.

Elixirr was founded in 2009, by Stephen Newton, Graham Busby, Ian Ferguson, Andy Curtis and Mark Goodyear, experienced business advisors who identified a market opportunity to provide bespoke, personal services as a 'challenger' to the traditional consultancy businesses in the market. Elixirr guides its clients to overcome challenges such as: future-proofing against technological disruption; development and roll-out of new propositions, products and services; incubating new businesses; navigating a more complex and multinational regulatory environment; and project management and implementation of major change programmes.

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the company's obligations under Article 17 of MAR.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUASSRUSUAOAR
Date   Source Headline
2nd Jun 20269:49 amRNSNotice of AGM and Dividend Timetable
20th May 20267:00 amRNSIssue of Equity - TRC Contingent Consideration
14th May 20268:38 amRNSHolding(s) in Company
29th Apr 20263:59 pmRNSHolding(s) in Company
29th Apr 202611:18 amRNSPublication of 2025 Annual Report
28th Apr 20265:59 pmRNSResult of Secondary Placing
28th Apr 20264:35 pmRNSProposed Secondary Placing
20th Apr 20267:00 amRNSResults for the year ended 31 December 2025
10th Apr 20267:00 amRNSHolding(s) in Company
27th Mar 20267:00 amRNSNotice of FY 25 Investor Presentation
23rd Mar 20267:00 amRNSGrant of Share Options
19th Mar 202610:09 amRNSDirector/PDMR Shareholding
27th Feb 202610:26 amRNSDirector/PDMR Shareholding
25th Feb 20267:00 amRNSDirector/PDMR Shareholding
2nd Feb 20267:00 amRNSAcquisition of Kvadrant Consulting A/S
30th Jan 20267:00 amRNSAppointment of Non-Executive Director
22nd Jan 20267:00 amRNSTrading Update and Interim Dividend
9th Jan 20264:37 pmRNSPDMR Shareholding
25th Sep 20258:08 amRNSDirector/PDMR Shareholding
22nd Sep 20257:01 amRNSInterim Results
22nd Sep 20257:00 amRNSAcquisition of TRC Advisory, LLC
18th Sep 20253:28 pmRNSIncrease in Debt Facilities to Support M&A
17th Sep 20257:00 amRNSNotice of H1 25 Investor Presentation
15th Sep 20257:00 amRNSMove from SETSqx to SETS
14th Jul 20257:00 amRNSTrading Update
10th Jul 20257:00 amRNSChange of Adviser
1st Jul 20258:00 amRNSReadmission - Elixirr International Plc
1st Jul 20257:00 amRNSAdmission to Main Market
26th Jun 20256:00 pmRNSElixirr International
24th Jun 20253:44 pmRNSPublication of Prospectus
24th Jun 202512:39 pmRNSResult of AGM
10th Jun 20257:00 amRNSGrant of Share Options
30th May 20257:00 amRNSMain Market Update & Capital Markets Day
29th May 20253:58 pmRNSPDMR Dealings and EBT Transfers
29th May 20257:00 amRNSPosting of Annual Report and Accounts
21st May 20257:00 amRNSCapital Markets Day
8th May 202512:21 pmRNSHoldings in Company – Employee Benefit Trust
28th Apr 20257:00 amRNSFinal Results
11th Mar 20257:00 amRNSNotice of FY24 Investor Presentation
18th Feb 20257:00 amRNSTrading Update
22nd Jan 20257:00 amRNSGrant of Restricted Share Awards
17th Jan 20251:40 pmRNSPurchase of Shares by Employee Benefit Trust
16th Jan 20253:05 pmRNSDirector/PDMR Shareholding
13th Jan 20258:06 amRNSBoard Appointment
6th Jan 20257:00 amRNSAppointment of Joint Broker
20th Dec 20244:20 pmRNSDirector/PDMR Shareholding
20th Dec 20247:00 amRNSInterim Dividend
10th Dec 20247:00 amRNSBoard Changes
25th Nov 20247:00 amRNSChange of Adviser
31st Oct 20247:00 amRNSPDMR Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.